Latest Comments

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Hemophilia gene therapies impress, but pricing doubts remain

Hemophilia gene therapies impress, but pricing doubts remain

Merck’s Keytruda stumbles in multiple myeloma

Merck’s Keytruda stumbles in multiple myeloma

FDA’s New Price-Tackling Strategy Puts Pressure on the Pharmaceutical Industry

FDA’s New Price-Tackling Strategy Puts Pressure on the Pharmaceutical Industry

Novel Approaches to US Cancer Research Funding on the Horizon

Novel Approaches to US Cancer Research Funding on the Horizon

EHA 2017: Novartis is Leading the CAR-T Cell Race

EHA 2017: Novartis is Leading the CAR-T Cell Race

EHA 2017: Targeting the Metabolic Control of the Epigenetic Machinery in R/R AML

EHA 2017: Targeting the Metabolic Control of the Epigenetic Machinery in R/R AML

EHA 2017: BCl-2 as an Emerging Target for AML

EHA 2017: BCl-2 as an Emerging Target for AML

EHA 2017: New Hope for Multiple Myeloma Patients

EHA 2017: New Hope for Multiple Myeloma Patients

Pharmaxis’ Bronchitol gears up for new drug application after meeting primary endpoint in phase III trial

Pharmaxis’ Bronchitol gears up for new drug application after meeting primary endpoint in phase III trial

Brexit: new alliance hopes to ensure healthcare stability in an uncertain future

Brexit: new alliance hopes to ensure healthcare stability in an uncertain future

Niche is the new normal: the growth of the orphan drugs market

Niche is the new normal: the growth of the orphan drugs market

COPD severity differs by severity system used

COPD severity differs by severity system used

NeuPSIG 2017: cell therapies may hold the key to opioid use in neuropathic pain

NeuPSIG 2017: cell therapies may hold the key to opioid use in neuropathic pain

EULAR 2017: Big pharma dives back into the lupus pipeline

EULAR 2017: Big pharma dives back into the lupus pipeline

EULAR 2017: Osteoarthritis pipeline product shows promise

EULAR 2017: Osteoarthritis pipeline product shows promise

DEVOTE trial update: ultra long-acting Insulin Tresiba as safe as insulin glargine

DEVOTE trial update: ultra long-acting Insulin Tresiba as safe as insulin glargine

GSK’s tafenoquine could spell the end for relapsing P. vivax malaria

GSK’s tafenoquine could spell the end for relapsing P. vivax malaria

EULAR 2017: Mixed Expectations on Use of Biosimilars in Rheumatoid Arthritis

EULAR 2017: Mixed Expectations on Use of Biosimilars in Rheumatoid Arthritis

Understanding the risk of over treatment in Type 2 Diabetes

Understanding the risk of over treatment in Type 2 Diabetes

EULAR 2017: progress made as scientist seek to unify Lupus field

EULAR 2017: progress made as scientist seek to unify Lupus field